Aleksander S. Popel
Affiliations: | Johns Hopkins University, Baltimore, MD |
Area:
Biomedical Engineering, Molecular Biology, General BiophysicsGoogle:
"Aleksander Popel"Mean distance: (not calculated yet)
Children
Sign in to add trainee| Esak Lee | grad student | (Biomechanics Tree) | |
| Feilim Mac Gabhann | grad student | 2007 | Johns Hopkins |
| Emmanouil D. Karagiannis | grad student | 2008 | Johns Hopkins |
| Jacob E. Koskimaki | grad student | 2012 | Johns Hopkins |
| Richard J Sove | post-doc | Johns Hopkins (Econometree) |
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Sargunas PR, Ariail E, Lima E Silva R, et al. (2025) Bispecific receptor decoy proteins inhibit ocular neovascularization via simultaneous blockade of vascular endothelial growth factor A and C. Molecular Therapy : the Journal of the American Society of Gene Therapy |
| Furukawa N, Yang W, Chao AR, et al. (2024) Chemokine-derived oncolytic peptide induces immunogenic cancer cell death and significantly suppresses tumor growth. Cell Death Discovery. 10: 161 |
| Furukawa N, Yang W, Chao A, et al. (2023) Chemokine-derived oncolytic peptide induces immunogenic cancer cell death and significantly suppresses tumor growth. Research Square |
| Zhang Y, Popel AS, Bazzazi H. (2023) Combining Multikinase Tyrosine Kinase Inhibitors Targeting the Vascular Endothelial Growth Factor and Cluster of Differentiation 47 Signaling Pathways Is Predicted to Increase the Efficacy of Antiangiogenic Combination Therapies. Acs Pharmacology & Translational Science. 6: 710-726 |
| Lima E Silva R, Mirando AC, Tzeng SY, et al. (2023) Anti-angiogenic collagen IV-derived peptide target engagement with αβ and αβ in ocular neovascularization models. Iscience. 26: 106078 |
| Sové RJ, Verma BK, Wang H, et al. (2022) Virtual clinical trials of anti-PD-1 and anti-CTLA-4 immunotherapy in advanced hepatocellular carcinoma using a quantitative systems pharmacology model. Journal For Immunotherapy of Cancer. 10 |
| Ruiz-Martinez A, Gong C, Wang H, et al. (2022) Simulations of tumor growth and response to immunotherapy by coupling a spatial agent-based model with a whole-patient quantitative systems pharmacology model. Plos Computational Biology. 18: e1010254 |
| Zhao C, Medeiros TX, Sové RJ, et al. (2021) A data-driven computational model enables integrative and mechanistic characterization of dynamic macrophage polarization. Iscience. 24: 102112 |
| Wang H, Ma H, Sové RJ, et al. (2021) Quantitative systems pharmacology model predictions for efficacy of atezolizumab and nab-paclitaxel in triple-negative breast cancer. Journal For Immunotherapy of Cancer. 9 |
| Mirando AC, Patil A, Rafie CI, et al. (2020) Regulation of the tumor immune microenvironment and vascular normalization in TNBC murine models by a novel peptide. Oncoimmunology. 9: 1760685 |